BiTEing the Tumor
by Shaji Kumar on June 3, 2020 at 7:55 pm
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
by Jayesh Desai on June 3, 2020 at 7:55 pm
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
by Loretta J. Nastoupil on June 3, 2020 at 7:55 pm
Reply to E. Javor et al
by Christine B. Ambrosone on June 3, 2020 at 7:55 pm
Challenges Faced by Medical Journals During the COVID-19 Pandemic
by Stephen A. Cannistra on June 3, 2020 at 7:55 pm
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children’s Oncology Group
by Rajen Mody on June 3, 2020 at 7:55 pm
Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline
by Ellie Maghami on June 3, 2020 at 7:55 pm
Avelumab in patients with gestational trophoblastic tumors resistant to monochemotherapy: Final outcomes of TROPHIMMUN phase II trial, cohort A.
by Benoit You on June 3, 2020 at 7:55 pm
The pediatric precision oncology study INFORM: Clinical outcome and benefit for molecular subgroups.
by Cornelis Martinus van Tilburg on June 3, 2020 at 7:55 pm
Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19).
by Jeremy Lyle Warner on June 3, 2020 at 7:55 pm
Sacituzumab Govitecan Becomes First ADC Approved for TNBC
on June 3, 2020 at 7:09 pm
Aditya Bardia, MD, MPH, discusses how the antibody-drug conjugate sacituzumab govitecan-hziy can address the unmet need in metastatic triple-negative breast cancer and the toxicities seen with the therapy.
Zanubrutinib Gains Approval in China for Relapsed/Refractory CLL/SLL and MCL
on June 3, 2020 at 5:50 pm
China's National Medical Products Administration has approved zanubrutinib (Brukinsa) for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma who have received at least 1 prior therapy, as well as for the treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy.
Encorafenib Plus Cetuximab Approved in Europe for BRAF V600E-Mutant mCRC
on June 3, 2020 at 4:46 pm
The European Commission has approved encorafenib (Braftovi) in combination with cetuximab (Erbitux) for the treatment of adult patients with BRAF V600E–mutant metastatic colorectal cancer who have received prior systemic therapy.
Continued OS Advantage With Encorafenib/Cetuximab Cements Role in BRAF+ mCRC
on June 3, 2020 at 4:44 pm
Scott Kopetz, MD, PhD, FACP, discusses the latest findings from the BEACON CRC study, the importance of testing for BRAF mutations in patients with CRC, and future directions with these agents.
Review Reveals Challenges of NGS Testing in Community Practices, Proactive Measures to Increase Utility
on June 3, 2020 at 3:53 pm
Jennifer Marie Suga, MD, discusses the importance of understanding the current limitations to next-generation sequencing in oncology, the impact of the study findings, and remaining challenges regarding NGS testing in the community setting.
FDA Grants Naxitamab Priority Review for Relapsed/Refractory High-Risk Neuroblastoma
on June 3, 2020 at 2:08 pm
The FDA has granted a priority review designation to a biologics license application for the investigational, humanized monoclonal antibody naxitamab (Danyelza) for the treatment of patients with relapsed/refractory high-risk neuroblastoma.
Isatuximab Approved in Europe for Relapsed/Refractory Myeloma
on June 2, 2020 at 7:39 pm
The European Commission has approved isatuximab in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma who have received ≥2 prior therapies.
Melflufen Continues Advance Through Myeloma Pipeline
on June 2, 2020 at 5:15 pm
An update on the phase 3 OCEAN study of melflufen in relapsed/refractory multiple myeloma reported that patients stayed on treatment longer than had been previously estimated.
CD71-Directed Probody-Drug Conjugate Shows Safety, Signals of Activity in Advanced Solid Tumors
on June 2, 2020 at 4:59 pm
The CD71-directed probody-drug conjugate of monomethyl auristatin E CX-2029 showed tolerability and antitumor activity in patients with advanced cancer.
Addition of Veliparib to Cisplatin Significantly Improves PFS in BRCA-Like Advanced TNBC
on June 2, 2020 at 4:42 pm
The addition of veliparib to cisplatin resulted in a significant improvement in progression-free survival and a trend toward improved overall survival in patients with BRCA-like triple-negative breast cancer.